F755 in South Dakota. Pick another state for the same tag.
Against expectation — 2025
South Dakota cites F755 less often than its own record predicts
Versus expected share0.93×
0.93 times the national share — cited less often here than elsewhere.
Share of South Dakota citations2.18%
Of every deficiency written in South Dakota in 2025, this is the portion that was F755.
South Dakota2.18%
National2.35%
Share of all citations that were F755.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What South Dakota surveyors wrote
F755 findings written in South Dakota, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
E · No harm, potential for more than minimal, patternAugust 28, 2026
Based on South Dakota Department of Health (SD DOH) facility reported incident (FRI) review, record review, interview, and policy review, the provider failed to ensure controlled substances were secured and accounted for regarding one of one Butrans (buprenorphine) transdermal patch (controlled narcotic skin patch that slowly releases an opiod medicine to treat severe pain) not being secured or available for administration for one of one resident (20) who had chronic pain, and for two of two observed residents (11 and 25) whose controlled medications were missing. Findings include:
1. Review of the provider's 6/13/26 SD DOH FRI revealed that on 6/12/26, resident 20's ordered Butrans transdermal patch was unaccounted for. …
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction